-
Ignyta's Entrectinib Data May Come By Year's End; Cantor Keeps Buy Rating, But Stock Slips 4%
Friday, June 17, 2016 - 2:04pm | 300Read More...Cantor analyst Mara Goldstein likes Ignyta Inc (NASDAQ: RXDX) shares for the opportunity provided by Entrectinib, which has multiple indications. As a result, she is confident that the drug could generate a bigger market than expected. The brokerage reiterated its rating of Buy and kept $18.00 as...
-
Why Shares of Ignyta Are Trading Higher
Monday, December 29, 2014 - 10:07am | 234Read More...Shares of Ignyta Inc (NASDAQ: RXDX) were trading higher by more than 6 percent during Monday's pre-market session after the company announced that the FDA designated its entrectinib, a lead product candidate an Orphan Drug for the treatment of neuroblastoma. The FDA grants Orphan Drug...
